Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Nature Communications|April 25, 2013
Magnetic barcode assay for genetic detection of pathogensMonty Liong, Anh N Hoang, Jaehoon Chung, et al.
Nature Genetics|April 26, 2011
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infectionChristopher B Ford, Philana Ling Lin, Michael R Chase, et al.
Elife|February 4, 2015
The evolution of drug resistance in clinical isolates of Candida albicansChristopher B Ford, Jason M Funt, Darren Abbey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2023
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile InfectionTimothy J Straub, Mary-Jane Lombardo, Jessica A Bryant, et al.
NPJ Biofilms and Microbiomes|February 6, 2021
Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infectionCharmaine Normington, Ines B Moura, Jessica A Bryant, et al.
Antibiotics (Basel, Switzerland)|September 23, 2022
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)Sahil Khanna, Matthew Sims, Thomas J Louie, et al.
The Journal of Infectious Diseases|August 2, 2025
Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infectionJessica A Bryant, Timothy J Straub, Darrell S Pardi, et al.
Gastroenterology|August 9, 2020
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative ColitisMatthew R Henn, Edward J O'Brien, Liyang Diao, et al.
Nature Medicine|January 6, 2026
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiomeJessica A Bryant, Marin Vulić, Emily A Walsh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
Pageof 3